Cocrystal Pharma, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
OPKO Health, Inc. purchased 5,474,053 shares of Cocrystal common stock for $5.0 million total at $0.9134 per share (Nasdaq Consolidated Bid Price on closing date), in a private placement under Section 4(a)(2) of the Securities Act. OPKO is described as a 'longtime investor' and co-founder Dr. Phillip Frost is chairman/CEO of OPKO and principal stockholder of Cocrystal. The investment is unregistered and restricted. Cocrystal expects Phase 1b norovirus trial topline data by end of Q4 2026.
Why this rating
$5M represents 43% of $11.6M market cap—substantial capital infusion for tiny biotech. Insider confidence signal from major stakeholder strengthens runway, though dilutive equity raise and clinical trial execution risk remain.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.